Morgan Stanley Harpoon Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.55 - $0.82 $1,100 - $1,640	2,001 Added 53.73%	5,725 $4,000
Q1 2023 May 15, 2023	BUY	$0.65 - $1.37 $509 - $1,074	784 Added 26.67%	3,724 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.6 - $1.41 $6,610 - $15,533	-11,017 Reduced 78.94%	2,940 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $2.56 $16,797 - $45,747	-17,870 Reduced 56.15%	13,957 $14,000
Q2 2022 Oct 27, 2022	BUY	$1.78 - $5.02 $22,915 - $64,627	12,874 Added 67.93%	31,827 $60,000
Q2 2022 Aug 15, 2022	BUY	$1.78 - $5.02 $22,915 - $64,627	12,874 Added 67.93%	31,827 $60,000
Q1 2022 Oct 27, 2022	SELL	$3.54 - $8.08 $45,573 - $104,021	-12,874 Reduced 40.45%	18,953 $94,000
Q1 2022 May 13, 2022	BUY	$3.54 - $8.08 $21,693 - $49,514	6,128 Added 47.78%	18,953 $94,000
Q4 2021 Feb 14, 2022	SELL	$5.69 - $7.83 $346,731 - $477,136	-60,937 Reduced 82.61%	12,825 $97,000
Q3 2021 Nov 15, 2021	BUY	$7.88 - $14.0 $581,244 - $1.03 Million	73,762 New	73,762 $583,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.